肝硬化作为合并症对医院再入院减少计划目标疾病再入院的影响
该纵向分析纳入2009至2013年纽约、佛罗里达和华盛顿州住院数据库中797,432例Medicare成人受益者,目标疾病为HRRP涵盖的肺炎、充血性心力衰竭和心肌梗死。肝硬化患者30天再入院率显著更高(29.3% vs 23.8%,P<0.001),且无肝硬化患者再入院率显著下降(年百分比变化-1.8%,P<0.001),而肝硬化患者无显著变化(P=0.39)。多变量分析显示肝硬化与30天再入院显著相关(OR 1.13,P<0.001)。
要点
- 肝硬化合并HRRP目标疾病时30天再入院率显著高于无肝硬化者(29.3% vs 23.8%)。
- 无肝硬化患者30天再入院率显著下降(年百分比变化-1.8%),肝硬化患者无显著变化(P=0.39)。
- 多变量分析显示肝硬化与30天再入院显著相关(OR 1.13,P<0.001)。
核心结论
- 当肝硬化作为合并症存在于HRRP目标疾病患者中时,再入院率更高且未改善。
- 需要针对性努力以改善HRRP队列中肝硬化及其他高风险合并症患者的结局。
研究设计与样本
- 对2009至2013年纽约、佛罗里达和华盛顿州住院数据库进行纵向分析。
- 纳入诊断相关组为HRRP目标疾病(肺炎、充血性心力衰竭、心肌梗死)的成人Medicare受益者。
- 排除无法评估再入院、既往肝移植或再入院不受HRRP惩罚的患者。
- 采用敏感性分析使用ICD-9-CM代码识别肺炎、充血性心力衰竭和心肌梗死住院。
主要发现
- 共纳入797,432例患者,其中8,964例(1.1%)有肝硬化。
- 肝硬化患者30天再入院率总体显著更高(29.3% vs 23.8%,P<0.001),肺炎和充血性心力衰竭亚组亦显著更高,但心肌梗死亚组无显著差异。
- 无肝硬化患者30天再入院率显著下降(年百分比变化-1.8%,P<0.001),肝硬化患者无显著变化(P=0.39)。
- 90天再入院结果类似。
- 敏感性分析证实上述发现。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Although the Hospital Readmissions Reduction Program (HRRP) has decreased readmissions in targeted conditions, outcomes in high-risk subgroups are unknown. This study analyzed the impact of cirrhosis as a comorbidity on readmissions in conditions subjected to the HRRP. METHODS: Using a longitudinal analysis of the New York, Florida, and Washington State inpatient databases from 2009 to 2013, adult Medicare beneficiaries with a diagnosis-related group of targeted conditions by the HRRP-pneumonia, congestive heart failure (CHF), and myocardial infarction (MI)-were included. Exclusion criteria included inability to assess for readmission, previous liver transplant, or having a readmission not subject to penalty under the HRRP. A sensitivity analysis used the International Classification of Diseases, 9th Revision, Clinical Modification codes to identify pneumonia, CHF, and MI hospitalizations. The primary outcome was 30-day readmission, with secondary outcomes including 90-day readmission, trends, and cirrhosis-specific risk factors for readmission. RESULTS: Of the 797,432 patients included, 8,964 (1.1%) had cirrhosis. Patients with cirrhosis had significantly higher 30-day readmissions overall (29.3% vs 23.8%, P < 0.001) and specifically for pneumonia and CHF, but not for MI. Thirty-day readmission rates significantly decreased in patients without cirrhosis (annual percent change -1.8%, P < 0.001), but not in patients with cirrhosis (P = 0.39). Similar findings were present for 90-day readmissions. A sensitivity analysis confirmed these findings. On multivariable analysis, cirrhosis was associated with significantly higher 30-day readmissions (odds ratio 1.13, P < 0.001). DISCUSSION: When cirrhosis is comorbid in patients with conditions subjected to the HRRP, readmissions are higher and have not improved. Focused efforts are needed to improve outcomes in cirrhosis and other high-risk comorbidities within the HRRP cohort.
引用
- Rosenblatt R, Cohen-Mekelburg S, Shen N, et al. Cirrhosis as a Comorbidity in Conditions Subject to the Hospital Readmissions Reduction Program. Am J Gastroenterol. 2019. PMID: 31180921. doi:10.14309/ajg.0000000000000257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。